Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction: A Modifiable Therapeutic Target?

Colin Berry; Robert Sykes

doi:10.1016/j.jcmg.2022.04.008

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction: A Modifiable Therapeutic Target?

JACC Cardiovasc Imaging. 2022 Jun;15(6):1012-1014. doi: 10.1016/j.jcmg.2022.04.008.

Authors

Colin Berry¹, Robert Sykes²

Affiliations

¹ British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, and The West of Scotland Heart and Lung Centre, NHS Golden Jubilee, Glasgow, Scotland, United Kingdom. Electronic address: colin.berry@glasgow.ac.uk.
² British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, and The West of Scotland Heart and Lung Centre, NHS Golden Jubilee, Glasgow, Scotland, United Kingdom.

PMID: 35680208
DOI: 10.1016/j.jcmg.2022.04.008

No abstract available

Keywords: cardiac magnetic resonance (CMR); heart failure with preserved ejection fraction (HFpEF); microvascular disease; myocardial fibrosis; pathophysiology; prognosis.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Heart Failure* / diagnostic imaging
Heart Failure* / drug therapy
Humans
Predictive Value of Tests
Stroke Volume
Ventricular Function, Left

Grants and funding

RE/18/6134217/BHF_/British Heart Foundation/United Kingdom